Connect your agent to akta.pro and build company lists like this across sectors and geos.
Ranked by relevance for C-Suite Appointments & Departures. Requested 15; the candidate pool was widened once and 11 companies carried a genuine, verifiable major executive departure in the window. The 10 highest-ranked are shown.
— The top seat turned over at 4 of the 10 companies — UnitedHealth Group, Sarepta Therapeutics, Danaher and Bausch + Lomb all changed CEOs in 2026, two of them via an interim or reinstated chief rather than a planned successor.
— Finance chiefs left at Pfizer, Zimmer Biomet and Insmed, each moving the stock — Zimmer Biomet hit a 13-year low on its CFO's immediate resignation and Insmed fell as much as 8.4% just before earnings, while Pfizer's CFO exit fed into an analyst downgrade.
— Departures cluster where regulatory or pipeline pressure is already high — UnitedHealth faces federal Medicare billing probes, Sarepta a narrowed FDA label, Pfizer a failed Phase 3 from its Seagen deal and Illumina a forced Grail divestment.
Companies ranked 10 of 15The 10 highest-ranked of 11 verified; the candidate pool was widened once
Highest relevance score 10/10UnitedHealth Group, Critical band, 7 distinct outlets
CEO or CFO exits among the 10 7 of 104 CEO and 3 CFO departures, Jan-Oct 2026
Editorial list Coverage: United States, companies Filter: Negative sentiment Window: Jan 1, 2026 – Oct 28, 2026 Ranked by: Incident relevance Source: akta.pro News Signals Compiled: Oct 28, 2026| # | Company name | Firmographics | Funding & investors | What company does | What happened & why | Sources |
|---|---|---|---|---|---|---|
| 01 | UnitedHealth Group unitedhealthgroup.com Critical | Founded 1974 Eden Prairie, North America USA | $7.57B Last raise 2025 | UnitedHealth Group is the largest US health insurer and healthcare services company, operating UnitedHealthcare and the Optum health services business. Value-Based Primary Care Organizations (Risk-Bearing) | UnitedHealth Group continued to navigate fallout from the unexpected departure of its CEO into 2026, reinstating its longtime former chief while facing a Justice Department probe into Medicare billing and an August 2026 shareholder derivative suit over governance failures. Why Coverage ties the leadership turnover to mounting regulatory and legal pressure, including federal probes into Medicare Advantage billing practices and alleged algorithmic care denials that shareholders say erased more than $277 billion in stockholder value. | 8 sources · 7 outlets |
| 02 | Pfizer pfizer.com Critical | Founded 1849 New York, North America USA | $38B Last raise 2025 | Pfizer is a global biopharmaceutical company that discovers, develops and markets medicines and vaccines. Specialty Care Pharmaceuticals | Pfizer announced in June 2026 that CFO Dave Denton would depart effective August 15, with an interim CFO stepping in, and HSBC downgraded the stock in July citing recent executive leadership changes alongside pipeline uncertainty. Why The departure landed alongside a Phase 3 failure for a cancer drug acquired in the $43 billion Seagen deal; analysts cited the combination of leadership change and pipeline setbacks for the downgrade, while the coverage notes management framed the exit as a routine transition unrelated to financial or operating results. | 23 sources · 14 outlets |
| 03 | Sarepta Therapeutics sarepta.com Critical | Founded 1987 Cambridge, North America USA | $2.88B Last raise 2025 | Sarepta Therapeutics is a Cambridge, Massachusetts biotech developing genetic medicines for rare diseases, including the Duchenne gene therapy Elevidys. Genetic & Genomic Rare Disease Therapeutics | Sarepta CEO Doug Ingram, who announced his retirement in February 2026 after nearly a decade in the role, was replaced in July 2026 by former Tessera Therapeutics CEO Michael Severino, capping a turbulent stretch for the company. Why Ingram attributed his departure to two family members being diagnosed with myotonic dystrophy; coverage places it against a strategic reset after Elevidys received a narrowed FDA label following fatal safety signals. | 17 sources · 11 outlets |
| 04 | Zimmer Biomet zimmerbiomet.com Critical | Founded 1927 Warsaw, North America USA | $2.75B Last raise 2025 | Zimmer Biomet is an Indiana-based manufacturer of orthopedic implants, robotics and musculoskeletal medical devices. Orthopedic Medical Devices | Zimmer Biomet's stock fell 10.5% to a 13-year low in April 2026 after CFO Suketu Upadhyay resigned with immediate effect, followed in September by a broader leadership reshuffle across its Americas and robotics businesses. Why The CFO left to pursue a new opportunity, per the coverage; investors reacted to the abrupt timing against a backdrop of a securities-law investigation into the company's emerging-market execution. | 3 sources · 3 outlets |
| 05 | Danaher danaher.com High | Founded 1969 Washington, North America USA | $8B Last raise 2026 | Danaher is a Washington, DC-based life sciences and diagnostics conglomerate supplying instruments and consumables to biopharma and clinical labs. Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) | Danaher shares fell 3.9% in October 2026 as Rainer Blair stepped down as CEO and Julie Sawyer Montgomery took over, alongside a muted 3-4% core revenue growth outlook. Why Coverage links the share decline to the CEO handoff coinciding with biopharma customers deferring spending; it does not give a specific reason for Blair's exit. | 2 sources · 2 outlets |
| 06 | Bausch & Lomb bausch.com High | Founded 1853 Bridgewater, North America USA | $4.98B Last raise 2025 | Bausch + Lomb is an eye health company making contact lenses, ophthalmic pharmaceuticals and surgical devices. Ophthalmology Specialty Pharmaceuticals | Bausch + Lomb CEO Brent Saunders departed in October 2026 and Thomas Appio was named interim CEO, sending shares down nearly 10% even as the company raised its full-year EBITDA guidance. Why The coverage does not state why Saunders left; the share drop is attributed to investor uncertainty over the abrupt move to an interim chief. | 3 sources · 3 outlets |
| 07 | Thermo Fisher Scientific thermofisher.com High | Founded 1956 Waltham, North America USA | $19.77B Last raise 2026 | Thermo Fisher Scientific is a Waltham, Massachusetts supplier of laboratory instruments, reagents and services to research, biopharma and clinical customers. Mass Spectrometry & Spectroscopy Instruments | Thermo Fisher announced in February 2026 that it would lay off 103 workers and close its Franklin, Massachusetts facility amid an executive shakeup, days after its 2026 profit outlook disappointed investors. Why Coverage attributes the pressure to cuts in research funding weighing on demand, which drove both the weak outlook and the restructuring alongside the leadership changes. | 2 sources · 2 outlets |
| 08 | Illumina illumina.com Elevated | Founded 1998 San Diego, North America USA | $2.28B Last raise 2026 | Illumina is a San Diego maker of DNA sequencing instruments and consumables. Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) | Illumina lost chief commercial officer Everett Cunningham in January 2026 when he left to become CEO of Quanterix, and in May 2026 the company agreed to divest Grail under a Federal Trade Commission order. Why Cunningham departed for a CEO role at another company; the Grail divestment followed the FTC's order unwinding Illumina's $7.1 billion 2021 acquisition. | 2 sources · 2 outlets |
| 09 | Insmed insmed.com Elevated | Founded 1988 Bridgewater, North America USA | $4.56B Last raise 2025 | Insmed is a commercial-stage biopharmaceutical company developing therapies for serious and rare pulmonary and inflammatory diseases. Pulmonology & Allergy Specialty Pharmaceuticals | Insmed shares fell as much as 8.4% in October 2026 after CFO Sara Bonstein said she would step down effective October 30, ending seven years with the company just ahead of its Q3 earnings call. Why The coverage gives no stated reason for the departure; analysts attributed the share drop to the leadership gap before earnings and read it as a sign a near-term takeover was less likely. | 2 sources · 2 outlets |
| 10 | Halozyme Therapeutics halozyme.com Elevated | Founded 2007 San Diego, North America USA | $4.04B Last raise 2026 | Halozyme Therapeutics develops drug-delivery technologies, licensing its ENHANZE subcutaneous platform to pharmaceutical partners. Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) | Halozyme shares fell 3.1% in after-hours trading in July 2026 after the company disclosed in an 8-K that Chief Operating Officer Cortney Caudill was leaving her position. Why The coverage reports the departure through the regulatory filing but does not give a reason for it. | 1 source |
akta.pro classifies this page's companies under Healthcare & Life Sciences, the sector covering firms that develop drugs and biologics, make medical devices and laboratory instruments, run diagnostics, and insure or deliver patient care. The ranked companies span biopharmaceuticals, life-science tools and diagnostics, orthopedic and eye-care devices, and managed care.
Executive turnover in this sector is closely watched because leaders steer long, regulated product cycles: a CEO or CFO change can signal a reset in pipeline strategy, capital allocation or regulatory posture. In 2026 many of the departures here coincided with FDA label changes, failed late-stage trials, federal billing probes or demand pressure from research-funding cuts.
This section describes the Healthcare & Life Sciences industry definition akta.pro uses to classify companies, not the C-Suite Appointments & Departures signal category the dashboard tracks.
NAICS and SIC are global standard industry classifications, shown as returned by akta.pro Company Data for the listed companies. The internal taxonomy is akta.pro's own industry tree: each code links to its akta.pro industry page, and the signal categories this page filters on are listed in the provenance line above.